Anti-Obesity Prescription Drugs Market by Type and Application - Global Industry Analysis & Forecast to 2027
Published On : October 2019 Pages : 180 Category: Pharma & Healthcare Report Code : HC106305
Anti-Obesity Prescription Drugs Market by Type (Orlistat, Bupropion and Naltrexone, Phentermine and Topiramate, Lorcaserin, Liraglutide, Others) Application (Hospitals Pharmacies, Retail Pharmacies, E-commerce) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The anti-obesity prescription drugs market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Anti-obesity medications are utilized in combination with diet and exercise in the treatment of obesity. The arrangement doesn't consider anti-obesity drugs to corpulence medications to be restoratively vital in the treatment of all patients with obesity as diet and exercise establish the pillar of treatment in most cases.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global Anti-Obesity Prescription Drugs Market size market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Bristol-Myers Squibb Co.
- Takeda Pharmaceutical Company Ltd.
- Eisai Co., Ltd.
- GlaxoSmithKline plc.
- Pfizer Inc.
- Shionogi USA, Inc.
- Vivus Inc.
- Zafgen Inc.
- Norgine BV
- Boehringer Ingelheim GmbH.
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Anti-Obesity Prescription Drugs Market , By Type, Estimates and Forecast, 2017-2027 ($Million)
o Electric Rolling Bucket Type
o Low Speed DC Motor Type
o Y-Motor Type
o High Speed DC Motor Type
o Others
· Anti-Obesity Prescription Drugs Market , By Application, Estimates and Forecast, 2017-2027 ($Million)
o Hospitals Pharmacies
o Retail Pharmacies
o E-commerce
· Anti-Obesity Prescription Drugs Market , By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Bristol-Myers Squibb Co.
o Takeda Pharmaceutical Company Ltd.
o Eisai Co., Ltd.
o GlaxoSmithKline plc.
o Pfizer Inc.
o Shionogi USA, Inc.
o Vivus Inc.
o Zafgen Inc.
o Norgine BV
o Boehringer Ingelheim GmbH.
· Anti-Obesity Prescription Drugs Market , By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Anti-Obesity Prescription Drugs Market , By Country
o U.S. Anti-Obesity Prescription Drugs Market
o Canada Anti-Obesity Prescription Drugs Market
o Mexico Anti-Obesity Prescription Drugs Market
o Europe
§ Europe Anti-Obesity Prescription Drugs Market , By Country
· Germany Anti-Obesity Prescription Drugs Market
o UK Anti-Obesity Prescription Drugs Market
o France Anti-Obesity Prescription Drugs Market
o Russia Anti-Obesity Prescription Drugs Market
o Italy Anti-Obesity Prescription Drugs Market
o Rest of Europe Anti-Obesity Prescription Drugs Market
o Asia-Pacific
§ Asia-Pacific Anti-Obesity Prescription Drugs Market , By Country
o China Anti-Obesity Prescription Drugs Market
o Japan Anti-Obesity Prescription Drugs Market
o South Korea Anti-Obesity Prescription Drugs Market
o India Anti-Obesity Prescription Drugs Market
o Southeast Asia Anti-Obesity Prescription Drugs Market
o Rest of Asia-Pacific Anti-Obesity Prescription Drugs Market
o South America
§ South America Anti-Obesity Prescription Drugs Market
o Brazil Anti-Obesity Prescription Drugs Market
o Argentina Anti-Obesity Prescription Drugs Market
o Columbia Anti-Obesity Prescription Drugs Market
o Rest of South America Anti-Obesity Prescription Drugs Market
o Middle East and Africa
§ Middle East and Africa Anti-Obesity Prescription Drugs Market
o Saudi Arabia Anti-Obesity Prescription Drugs Market
o UAE Anti-Obesity Prescription Drugs Market
o Egypt Anti-Obesity Prescription Drugs Market
o Nigeria Anti-Obesity Prescription Drugs Market
o South Africa Anti-Obesity Prescription Drugs Market
o Rest of MEA Anti-Obesity Prescription Drugs Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Anti-Obesity Prescription Drugs Market, By Type
5.1. Introduction
5.2. Global Anti-Obesity Prescription Drugs Revenue and Market Share by Type (2017-2027)
5.2.1. Global Anti-Obesity Prescription Drugs Revenue and Revenue Share by Type (2017-2027)
5.3. Orlistat
5.3.1. Global Orlistat Revenue and Growth Rate (2017-2027)
5.4. Bupropion and Naltrexone
5.4.1. Global Bupropion and Naltrexone Revenue and Growth Rate (2017-2027)
5.5. Phentermine and Topiramate
5.5.1. Global Phentermine and Topiramate Revenue and Growth Rate (2017-2027)
5.6. Lorcaserin
5.6.1. Global Lorcaserin Revenue and Growth Rate (2017-2027)
5.7. Liraglutide
5.7.1. Global Liraglutide Revenue and Growth Rate (2017-2027)
5.8. Others
5.8.1. Global Others Revenue and Growth Rate (2017-2027)
6. Anti-Obesity Prescription Drugs Market, By Application
6.1. Introduction
6.2. Global Anti-Obesity Prescription Drugs Revenue and Market Share by Application (2017-2027)
6.2.1. Global Anti-Obesity Prescription Drugs Revenue and Revenue Share by Application (2017-2027)
6.3. Hospitals Pharmacies
6.3.1. Global Hospitals Pharmacies Revenue and Growth Rate (2017-2027)
6.4. Retail Pharmacies
6.4.1. Global Retail Pharmacies Revenue and Growth Rate (2017-2027)
6.5. E-commerce
6.5.1. Global E-commerce Revenue and Growth Rate (2017-2027)
7. Anti-Obesity Prescription Drugs Market, By Region
7.1. Introduction
7.2. Global Anti-Obesity Prescription Drugs Revenue and Market Share by Regions
7.2.1. Global Anti-Obesity Prescription Drugs Revenue by Regions (2017-2027)
7.3. North America Anti-Obesity Prescription Drugs by Countries
7.3.1. North America Anti-Obesity Prescription Drugs Revenue and Growth Rate (2017-2027)
7.3.2. North America Anti-Obesity Prescription Drugs Revenue (Million USD) by Countries (2017-2027)
7.3.3. United States
7.3.3.1. United States Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.4. Canada
7.3.4.1. Canada Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.5. Mexico
7.3.5.1. Mexico Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4. Europe Anti-Obesity Prescription Drugs by Countries
7.4.1. Europe Anti-Obesity Prescription Drugs Revenue and Growth Rate (2017-2027)
7.4.2. Europe Anti-Obesity Prescription Drugs Revenue (Million USD) by Countries (2017-2027)
7.4.3. Germany
7.4.3.1. Germany Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.4. France
7.4.4.1. France Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.5. UK
7.4.5.1. UK Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.6. Russia
7.4.6.1. Russia Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.7. Italy
7.4.7.1. Italy Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5. Asia-Pacific Anti-Obesity Prescription Drugs by Countries
7.5.1. Asia-Pacific Anti-Obesity Prescription Drugs Revenue and Growth Rate (2017-2027)
7.5.2. Asia-Pacific Anti-Obesity Prescription Drugs Revenue (Million USD) by Countries (2017-2027)
7.5.3. China
7.5.3.1. China Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.4. Japan
7.5.4.1. Japan Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.5. Korea
7.5.5.1. Korea Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.6. India
7.5.6.1. India Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6. South America Anti-Obesity Prescription Drugs by Countries
7.6.1. South America Anti-Obesity Prescription Drugs Revenue and Growth Rate (2017-2027)
7.6.2. South America Anti-Obesity Prescription Drugs Revenue (Million USD) by Countries (2017-2027)
7.6.3. Brazil
7.6.3.1. Brazil Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.4. Argentina
7.6.4.1. Argentina Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.5. Columbia
7.6.5.1. Columbia Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7. Middle East and Africa Anti-Obesity Prescription Drugs by Countries
7.7.1. Middle East and Africa Anti-Obesity Prescription Drugs Revenue and Growth Rate (2017-2027)
7.7.2. Middle East and Africa Anti-Obesity Prescription Drugs Revenue (Million USD) by Countries (2017-2027)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.5. Egypt
7.7.5.1. Egypt Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.6. Nigeria
7.7.6.1. Nigeria Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.7. South Africa
7.7.7.1. South Africa Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.8. Turkey
7.7.8.1. Turkey Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8. Company Profiles
8.1. Bristol-Myers Squibb Co.
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. Takeda Pharmaceutical Company Ltd.
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. Eisai Co., Ltd.
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. GlaxoSmithKline plc.
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. Pfizer Inc.
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. Shionogi USA, Inc.
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
8.7. Vivus Inc.
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Financial Overview
8.8. Zafgen Inc.
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Financial Overview
8.9. Norgine BV
8.9.1. Business Overview
8.9.2. Service Portfolio
8.9.3. Strategic Developments
8.9.4. Financial Overview
8.10. Boehringer Ingelheim GmbH.
8.10.1. Business Overview
8.10.2. Service Portfolio
8.10.3. Strategic Developments
8.10.4. Financial Overview
9. Anti-Obesity Prescription Drugs Market Forecast (2017-2027)
9.1. Global Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
9.2. Anti-Obesity Prescription Drugs Market Forecast by Regions (2017-2027)
9.2.1. North America Anti-Obesity Prescription Drugs Market Forecast (2017-2027)
9.2.1.1. United States Anti-Obesity Prescription Drugs Market Forecast (2017-2027)
9.2.1.2. Canada Anti-Obesity Prescription Drugs Market Forecast (2017-2027)
9.2.1.3. Mexico Anti-Obesity Prescription Drugs Market Forecast (2017-2027)
9.2.2. Europe Anti-Obesity Prescription Drugs Market Forecast (2017-2027)
9.2.2.1. Germany Anti-Obesity Prescription Drugs Market Forecast (2017-2027)
9.2.2.2. France Anti-Obesity Prescription Drugs Market Forecast (2017-2027)
9.2.2.3. UK Anti-Obesity Prescription Drugs Market Forecast (2017-2027)
9.2.2.4. Russia Anti-Obesity Prescription Drugs Market Forecast (2017-2027)
9.2.2.5. Italy Anti-Obesity Prescription Drugs Market Forecast (2017-2027)
9.2.2.6. Rest of Europe Anti-Obesity Prescription Drugs Market Forecast (2017-2027)
9.2.3. Asia-Pacific Anti-Obesity Prescription Drugs Market Forecast (2017-2027)
9.2.3.1. China Anti-Obesity Prescription Drugs Market Forecast (2017-2027)
9.2.3.2. Japan Anti-Obesity Prescription Drugs Market Forecast (2017-2027)
9.2.3.3. Korea Anti-Obesity Prescription Drugs Market Forecast (2017-2027)
9.2.3.4. India Anti-Obesity Prescription Drugs Market Forecast (2017-2027)
9.2.3.5. Southeast Asia Anti-Obesity Prescription Drugs Market Forecast (2017-2027)
9.2.3.6. Rest of Asia-Pacific Anti-Obesity Prescription Drugs Market Forecast (2017-2027)
9.2.4. South America Anti-Obesity Prescription Drugs Market Forecast (2017-2027)
9.2.4.1. Brazil Anti-Obesity Prescription Drugs Market Forecast (2017-2027)
9.2.4.2. Argentina Anti-Obesity Prescription Drugs Market Forecast (2017-2027)
9.2.4.3. Columbia Anti-Obesity Prescription Drugs Market Forecast (2017-2027)
9.2.4.4. Rest of South America Anti-Obesity Prescription Drugs Market Forecast (2017-2027)
9.2.5. Middle East and Africa Anti-Obesity Prescription Drugs Market Forecast (2017-2027)
9.2.5.1. Saudi Arabia Anti-Obesity Prescription Drugs Market Forecast (2017-2027)
9.2.5.2. United Arab Emirates Anti-Obesity Prescription Drugs Market Forecast (2017-2027)
9.2.5.3. Egypt Anti-Obesity Prescription Drugs Market Forecast (2017-2027)
9.2.5.4. Nigeria Anti-Obesity Prescription Drugs Market Forecast (2017-2027)
9.2.5.5. South Africa Anti-Obesity Prescription Drugs Market Forecast (2017-2027)
9.2.5.6. Turkey Anti-Obesity Prescription Drugs Market Forecast (2017-2027)
9.2.5.7. Rest of Middle East and Africa Anti-Obesity Prescription Drugs Market Forecast (2017-2027)
9.3. Anti-Obesity Prescription Drugs Market Forecast by Type (2017-2027)
9.3.1. Anti-Obesity Prescription Drugs Forecast by Type (2017-2027)
9.3.2. Anti-Obesity Prescription Drugs Market Share Forecast by Type (2017-2027)
9.4. Anti-Obesity Prescription Drugs Market Forecast by Application (2017-2027)
9.4.1. Anti-Obesity Prescription Drugs Forecast by Application (2017-2027)
9.4.2. Anti-Obesity Prescription Drugs Market Share Forecast by Application (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Anti-Obesity Prescription Drugs Revenue and Revenue Share by Type (2017-2018)
Figure Global Orlistat Revenue and Growth Rate (2017-2018)
Figure Global Bupropion and Naltrexone Revenue and Growth Rate (2017-2018)
Figure Global Phentermine and Topiramate Revenue and Growth Rate (2017-2018)
Figure Global Lorcaserin Revenue and Growth Rate (2017-2018)
Figure Global Liraglutide Revenue and Growth Rate (2017-2018)
Figure Global Others Revenue and Growth Rate (2017-2018)
Table Global Anti-Obesity Prescription Drugs Revenue and Revenue Share by Application (2017-2018)
Figure Global Hospitals Pharmacies Revenue and Growth Rate (2017-2018)
Figure Global Retail Pharmacies Revenue and Growth Rate (2017-2018)
Figure Global E-commerce Revenue and Growth Rate (2017-2018)
Table Global Anti-Obesity Prescription Drugs Revenue by Regions (2017-2018)
Figure North America Anti-Obesity Prescription Drugs Growth Rate (2017-2018)
Figure North America Anti-Obesity Prescription Drugs Revenue and Growth Rate (2017-2018)
Figure North America Anti-Obesity Prescription Drugs by Countries (2017-2018)
Figure North America Anti-Obesity Prescription Drugs Revenue (Million USD) by Countries (2017-2018)
Figure United States Anti-Obesity Prescription Drugs Growth Rate (2017-2018)
Figure United States Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Anti-Obesity Prescription Drugs Growth Rate (2017-2018)
Figure Canada Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Anti-Obesity Prescription Drugs Growth Rate (2017-2018)
Figure Mexico Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Anti-Obesity Prescription Drugs Growth Rate (2017-2018)
Figure Europe Anti-Obesity Prescription Drugs Revenue and Growth Rate (2017-2018)
Figure Europe Anti-Obesity Prescription Drugs by Countries (2017-2018)
Figure Europe Anti-Obesity Prescription Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Germany Anti-Obesity Prescription Drugs Growth Rate (2017-2018)
Figure Germany Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Anti-Obesity Prescription Drugs Growth Rate (2017-2018)
Figure France Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Anti-Obesity Prescription Drugs Growth Rate (2017-2018)
Figure UK Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Anti-Obesity Prescription Drugs Growth Rate (2017-2018)
Figure Russia Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Anti-Obesity Prescription Drugs Growth Rate (2017-2018)
Figure Italy Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Anti-Obesity Prescription Drugs Growth Rate (2017-2018)
Figure Rest of Europe Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Anti-Obesity Prescription Drugs Growth Rate (2017-2018)
Figure Asia-Pacific Anti-Obesity Prescription Drugs Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Anti-Obesity Prescription Drugs by Countries (2017-2018)
Figure Asia-Pacific Anti-Obesity Prescription Drugs Revenue (Million USD) by Countries (2017-2018)
Figure China Anti-Obesity Prescription Drugs Growth Rate (2017-2018)
Figure China Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Anti-Obesity Prescription Drugs Growth Rate (2017-2018)
Figure Japan Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Anti-Obesity Prescription Drugs Growth Rate (2017-2018)
Figure Korea Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Anti-Obesity Prescription Drugs Growth Rate (2017-2018)
Figure India Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Anti-Obesity Prescription Drugs Growth Rate (2017-2018)
Figure Southeast Asia Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Anti-Obesity Prescription Drugs Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Anti-Obesity Prescription Drugs Growth Rate (2017-2018)
Figure South America Anti-Obesity Prescription Drugs Revenue and Growth Rate (2017-2018)
Figure South America Anti-Obesity Prescription Drugs by Countries (2017-2018)
Figure South America Anti-Obesity Prescription Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Anti-Obesity Prescription Drugs Growth Rate (2017-2018)
Figure Brazil Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Anti-Obesity Prescription Drugs Growth Rate (2017-2018)
Figure Argentina Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Anti-Obesity Prescription Drugs Growth Rate (2017-2018)
Figure Columbia Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Anti-Obesity Prescription Drugs Growth Rate (2017-2018)
Figure Rest of South America Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Anti-Obesity Prescription Drugs Growth Rate (2017-2018)
Figure Middle East and Africa Anti-Obesity Prescription Drugs Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Anti-Obesity Prescription Drugs by Countries (2017-2018)
Figure Middle East and Africa Anti-Obesity Prescription Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Anti-Obesity Prescription Drugs Growth Rate (2017-2018)
Figure Saudi Arabia Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Anti-Obesity Prescription Drugs Growth Rate (2017-2018)
Figure United Arab Emirates Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Anti-Obesity Prescription Drugs Growth Rate (2017-2018)
Figure Egypt Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Anti-Obesity Prescription Drugs Growth Rate (2017-2018)
Figure Nigeria Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Anti-Obesity Prescription Drugs Growth Rate (2017-2018)
Figure South Africa Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Anti-Obesity Prescription Drugs Growth Rate (2017-2018)
Figure Turkey Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Anti-Obesity Prescription Drugs Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Table Bristol-Myers Squibb Co. Anti-Obesity Prescription Drugs Financial Overview
Table Takeda Pharmaceutical Company Ltd. Anti-Obesity Prescription Drugs Financial Overview
Table Eisai Co., Ltd. Anti-Obesity Prescription Drugs Financial Overview
Table GlaxoSmithKline plc. Anti-Obesity Prescription Drugs Financial Overview
Table Pfizer Inc. Anti-Obesity Prescription Drugs Financial Overview
Table Shionogi USA, Inc. Anti-Obesity Prescription Drugs Financial Overview
Table Vivus Inc. Anti-Obesity Prescription Drugs Financial Overview
Table Zafgen Inc. Anti-Obesity Prescription Drugs Financial Overview
Table Norgine BV Anti-Obesity Prescription Drugs Financial Overview
Table Boehringer Ingelheim GmbH. Anti-Obesity Prescription Drugs Financial Overview
Figure Global Anti-Obesity Prescription Drugs Revenue (Millions USD) and Growth Rate (2018-2025)
Table Anti-Obesity Prescription Drugs Market Forecast by Regions (2018-2025)
Figure North America Anti-Obesity Prescription Drugs Market Forecast (2018-2025)
Figure United States Anti-Obesity Prescription Drugs Market Forecast (2018-2025)
Figure Canada Anti-Obesity Prescription Drugs Market Forecast (2018-2025)
Figure Mexico Anti-Obesity Prescription Drugs Market Forecast (2018-2025)
Figure Europe Anti-Obesity Prescription Drugs Market Forecast (2018-2025)
Figure Germany Anti-Obesity Prescription Drugs Market Forecast (2018-2025)
Figure France Anti-Obesity Prescription Drugs Market Forecast (2018-2025)
Figure UK Anti-Obesity Prescription Drugs Market Forecast (2018-2025)
Figure Russia Anti-Obesity Prescription Drugs Market Forecast (2018-2025)
Figure Italy Anti-Obesity Prescription Drugs Market Forecast (2018-2025)
Figure Rest of Europe Anti-Obesity Prescription Drugs Market Forecast (2018-2025)
Figure Asia-Pacific Anti-Obesity Prescription Drugs Market Forecast (2018-2025)
Figure China Anti-Obesity Prescription Drugs Market Forecast (2018-2025)
Figure Japan Anti-Obesity Prescription Drugs Market Forecast (2018-2025)
Figure Korea Anti-Obesity Prescription Drugs Market Forecast (2018-2025)
Figure India Anti-Obesity Prescription Drugs Market Forecast (2018-2025)
Figure Southeast Asia Anti-Obesity Prescription Drugs Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Anti-Obesity Prescription Drugs Market Forecast (2018-2025)
Figure South America Anti-Obesity Prescription Drugs Market Forecast (2018-2025)
Figure Brazil Anti-Obesity Prescription Drugs Market Forecast (2018-2025)
Figure Argentina Anti-Obesity Prescription Drugs Market Forecast (2018-2025)
Figure Columbia Anti-Obesity Prescription Drugs Market Forecast (2018-2025)
Figure Rest of South America Anti-Obesity Prescription Drugs Market Forecast (2018-2025)
Figure Middle East and Africa Anti-Obesity Prescription Drugs Market Forecast (2018-2025)
Figure Saudi Arabia Anti-Obesity Prescription Drugs Market Forecast (2018-2025)
Figure United Arab Emirates Anti-Obesity Prescription Drugs Market Forecast (2018-2025)
Figure Egypt Anti-Obesity Prescription Drugs Market Forecast (2018-2025)
Figure Nigeria Anti-Obesity Prescription Drugs Market Forecast (2018-2025)
Figure South Africa Anti-Obesity Prescription Drugs Market Forecast (2018-2025)
Figure Turkey Anti-Obesity Prescription Drugs Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Anti-Obesity Prescription Drugs Market Forecast (2018-2025)
Figure Global Anti-Obesity Prescription Drugs Forecast by Type (2018-2025)
Figure Global Anti-Obesity Prescription Drugs Market Share Forecast by Type (2018-2025)
Figure Global Anti-Obesity Prescription Drugs Forecast by Type (2018-2025)
Figure Global Anti-Obesity Prescription Drugs Forecast by Application (2018-2025)
Figure Global Anti-Obesity Prescription Drugs Market Share Forecast by Application (2018-2025)
Figure Global Anti-Obesity Prescription Drugs Forecast by Application (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|